

George Papatheodoridis

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4080101/publications.pdf>

Version: 2024-02-01

485
papers

28,226
citations

10351

72
h-index

6818

155
g-index

506
all docs

506
docs citations

506
times ranked

20740
citing authors

#	ARTICLE	IF	CITATIONS
1	EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. Journal of Hepatology, 2017, 67, 370-398.	1.8	3,803
2	EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection. Journal of Hepatology, 2012, 57, 167-185.	1.8	2,784
3	Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. The Lancet Gastroenterology and Hepatology, 2017, 2, 161-176.	3.7	1,619
4	Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. The Lancet Gastroenterology and Hepatology, 2018, 3, 383-403.	3.7	1,241
5	2-Year GLOBE Trial Results: Telbivudine Is Superior to Lamivudine in Patients With Chronic Hepatitis B. Gastroenterology, 2009, 136, 486-495.	0.6	527
6	Risk of hepatocellular carcinoma in chronic hepatitis B: Assessment and modification with current antiviral therapy. Journal of Hepatology, 2015, 62, 956-967.	1.8	398
7	Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: A systematic review. Journal of Hepatology, 2010, 53, 348-356.	1.8	397
8	PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy. Journal of Hepatology, 2016, 64, 800-806.	1.8	358
9	Systematic review: the model for end-stage liver disease - should it replace Child-Pugh's classification for assessing prognosis in cirrhosis?. Alimentary Pharmacology and Therapeutics, 2005, 22, 1079-1089.	1.9	351
10	Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal Impairment. New England Journal of Medicine, 2017, 377, 1448-1455.	13.9	348
11	Efficacy of Long-Term Lamivudine Monotherapy in Patients With Hepatitis B e Antigen-“Negative Chronic Hepatitis B. Hepatology, 2000, 32, 847-851.	3.6	323
12	Transjugular intrahepatic portosystemic shunt compared with endoscopic treatment for prevention of variceal rebleeding: A meta-analysis. Hepatology, 1999, 30, 612-622.	3.6	320
13	Combination of Tenofovir Disoproxil Fumarate and Peginterferon Î±-2a Increases Loss of Hepatitis B Surface Antigen in Patients With Chronic Hepatitis B. Gastroenterology, 2016, 150, 134-144.e10.	0.6	284
14	The long-term outcome of interferon-Î± treated and untreated patients with HBeAg-negative chronic hepatitis B. Journal of Hepatology, 2001, 34, 306-313.	1.8	279
15	Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease. Hepatology, 2011, 53, 62-72.	3.6	274
16	Liver grafts from anti-hepatitis B core positive donors: A systematic review. Journal of Hepatology, 2010, 52, 272-279.	1.8	253
17	The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B. Hepatology, 2017, 66, 1444-1453.	3.6	239
18	Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study. The Lancet Gastroenterology and Hepatology, 2022, 7, 396-415.	3.7	237

#	ARTICLE	IF	CITATIONS
19	Hepatitis B e Antigen-Negative Chronic Hepatitis B: Natural History and Treatment. <i>Seminars in Liver Disease</i> , 2006, 26, 130-141.	1.8	230
20	Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine. <i>Hepatology</i> , 2005, 42, 121-129.	3.6	229
21	Discontinuation of oral antivirals in chronic hepatitis B: A systematic review. <i>Hepatology</i> , 2016, 63, 1481-1492.	3.6	215
22	Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 325-336.	3.7	208
23	Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference. <i>Journal of Hepatology</i> , 2020, 72, 539-557.	1.8	208
24	Effects of lifestyle interventions on clinical characteristics of patients with non-alcoholic fatty liver disease: A meta-analysis. <i>Metabolism: Clinical and Experimental</i> , 2017, 68, 119-132.	1.5	192
25	Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease. <i>Hepatology</i> , 2002, 36, 219-226.	3.6	187
26	Therapeutic strategies in the management of patients with chronic hepatitis B virus infection. <i>Lancet Infectious Diseases</i> , The, 2008, 8, 167-178.	4.6	182
27	Adherence to the Mediterranean diet is associated with the severity of non-alcoholic fatty liver disease. <i>Clinical Nutrition</i> , 2014, 33, 678-683.	2.3	182
28	Risk factors for recurrence of primary sclerosing cholangitis after liver transplantation. <i>Liver Transplantation</i> , 2008, 14, 138-143.	1.3	174
29	Ulcerative colitis has an aggressive course after orthotopic liver transplantation for primary sclerosing cholangitis. <i>Gut</i> , 1998, 43, 639-644.	6.1	173
30	The Evolving Role of Leptin and Adiponectin in Chronic Liver Diseases. <i>American Journal of Gastroenterology</i> , 2006, 101, 2629-2640.	0.2	168
31	Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece cohort study. <i>Gut</i> , 2011, 60, 1109-1116.	6.1	159
32	aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis. <i>Journal of Hepatology</i> , 2020, 73, 1368-1378.	1.8	158
33	Follow-up and indications for liver biopsy in HBeAg-negative chronic hepatitis B virus infection with persistently normal ALT: A systematic review. <i>Journal of Hepatology</i> , 2012, 57, 196-202.	1.8	152
34	Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: A systematic review and meta-analysis. <i>Journal of Hepatology</i> , 2021, 75, 770-785.	1.8	149
35	COVID-19 pandemic and worldwide organ transplantation: a population-based study. <i>Lancet Public Health</i> , The, 2021, 6, e709-e719.	4.7	139
36	Incidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B patients receiving entecavir or tenofovir. <i>Journal of Hepatology</i> , 2015, 62, 363-370.	1.8	138

#	ARTICLE	IF	CITATIONS
37	Long-term safety of anti-TNF treatment in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1352-1355.	0.5	133
38	High Genetic Barrier Nucleos(t)ide Analogue(s) for Prophylaxis From Hepatitis B Virus Recurrence After Liver Transplantation: A Systematic Review. <i>American Journal of Transplantation</i> , 2013, 13, 353-362.	2.6	128
39	Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): a randomised, placebo controlled, phase 2 trial. <i>Lancet Infectious Diseases</i> , The, 2019, 19, 275-286.	4.6	128
40	Effects of <i>Helicobacter pylori</i> and Nonsteroidal Anti-Inflammatory Drugs on Peptic Ulcer Disease: A Systematic Review. <i>Clinical Gastroenterology and Hepatology</i> , 2006, 4, 130-142.	2.4	124
41	A cross-sectional study of the public health response to non-alcoholic fatty liver disease in Europe. <i>Journal of Hepatology</i> , 2020, 72, 14-24.	1.8	123
42	Efficacy of long term lamivudine therapy in HBeAg negative chronic hepatitis B. <i>Journal of Hepatology</i> , 2000, 32, 98.	1.8	119
43	Nucleoside Analogues for Chronic Hepatitis B: Antiviral Efficacy and Viral Resistance. <i>American Journal of Gastroenterology</i> , 2002, 97, 1618-1628.	0.2	119
44	The present and future disease burden of hepatitis C virus (HCV) infections with today's treatment paradigm – volume 2. <i>Journal of Viral Hepatitis</i> , 2015, 22, 26-45.	1.0	117
45	Effect of interferon therapy on the development of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis: a meta-analysis. <i>Alimentary Pharmacology and Therapeutics</i> , 2001, 15, 689-698.	1.9	115
46	Is there a meaningful serum hepatitis B virus DNA cutoff level for therapeutic decisions in hepatitis B e antigen-negative chronic hepatitis B virus infection?. <i>Hepatology</i> , 2008, 48, 1451-1459.	3.6	114
47	Refining the Baveno VI elastography criteria for the definition of compensated advanced chronic liver disease. <i>Journal of Hepatology</i> , 2021, 74, 1109-1116.	1.8	112
48	Prevalence and clinical course of hepatitis delta infection in Greece: A 13-year prospective study. <i>Journal of Hepatology</i> , 2013, 59, 949-956.	1.8	107
49	Effects of Alcohol Consumption and Metabolic Syndrome on Mortality in Patients With Nonalcoholic and Alcohol-Related Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1625-1633.e1.	2.4	107
50	Adipokines in Nonalcoholic Steatohepatitis: From Pathogenesis to Implications in Diagnosis and Therapy. <i>Mediators of Inflammation</i> , 2009, 2009, 1-8.	1.4	105
51	Hepatitis B immunoglobulin and/or nucleos(t)ide analogues for prophylaxis against hepatitis b virus recurrence after liver transplantation: A systematic review. <i>Liver Transplantation</i> , 2011, 17, 1176-1190.	1.3	105
52	Intestinal Bacteria Composition and Translocation of Bacteria in Inflammatory Bowel Disease. <i>PLoS ONE</i> , 2017, 12, e0170034.	1.1	103
53	Increased Arterial Stiffness and Impaired Endothelial Function in Nonalcoholic Fatty Liver Disease: A Pilot Study. <i>American Journal of Hypertension</i> , 2010, 23, 1183-1189.	1.0	101
54	Improvements in clinical characteristics of patients with non-alcoholic fatty liver disease, after an intervention based on the Mediterranean lifestyle: a randomised controlled clinical trial. <i>British Journal of Nutrition</i> , 2018, 120, 164-175.	1.2	100

#	ARTICLE	IF	CITATIONS
55	Telbivudine Improves Renal Function in Patients With Chronic Hepatitis B. <i>Gastroenterology</i> , 2014, 146, 138-146.e5.	0.6	99
56	Diabetes mellitus in chronic hepatitis B and C: prevalence and potential association with the extent of liver fibrosis. <i>Journal of Viral Hepatitis</i> , 2006, 13, 303-310.	1.0	97
57	Immunosuppression and donor age with respect to severity of HCV recurrence after liver transplantation. <i>Liver Transplantation</i> , 2005, 11, 386-395.	1.3	95
58	Thrombotic risk factors and extent of liver fibrosis in chronic viral hepatitis. <i>Gut</i> , 2003, 52, 404-409.	6.1	94
59	Diagnosis and management of pre-core mutant chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2001, 8, 311-321.	1.0	93
60	Historical epidemiology of hepatitis C virus (<scp>HCV</scp>) in select countries – volume 2. <i>Journal of Viral Hepatitis</i> , 2015, 22, 6-25.	1.0	92
61	Significance of Hepatitis B Viremia Levels Determined by A Quantitative Polymerase Chain Reaction Assay in Patients With Hepatitis B E Antigen–Negative Chronic Hepatitis B Virus Infection. <i>American Journal of Gastroenterology</i> , 2003, 98, 2261-2267.	0.2	91
62	Antiviral therapy reduces portal pressure in patients with cirrhosis due to HBeAg-negative chronic hepatitis B and significant portal hypertension. <i>Journal of Hepatology</i> , 2009, 51, 468-474.	1.8	91
63	Optimal management of hepatitis B virus infection – EASL Special Conference. <i>Journal of Hepatology</i> , 2015, 63, 1238-1253.	1.8	91
64	THE ROLE OF DIFFERENT IMMUNOSUPPRESSION IN THE LONG-TERM HISTOLOGICAL OUTCOME OF HCV REINFECTION AFTER LIVER TRANSPLANTATION FOR HCV CIRRHOSIS. <i>Transplantation</i> , 2001, 72, 412-418.	0.5	89
65	Eight-year survival in chronic hepatitis B patients under long-term entecavir or tenofovir therapy is similar to the general population. <i>Journal of Hepatology</i> , 2018, 68, 1129-1136.	1.8	88
66	Infection and hemostasis in decompensated cirrhosis: A prospective study using thrombelastography. <i>Hepatology</i> , 1999, 29, 1085-1090.	3.6	83
67	Correlation of NK T-like CD3+CD56+ cells and CD4+CD25+(hi) regulatory T cells with VEGF and TNF α in ascites from advanced ovarian cancer: Association with platinum resistance and prognosis in patients receiving first-line, platinum-based chemotherapy. <i>Gynecologic Oncology</i> , 2008, 108, 421-427.	0.6	83
68	MELD vs Child-Pugh and creatinine-modified Child-Pugh score for predicting survival in patients with decompensated cirrhosis. <i>World Journal of Gastroenterology</i> , 2005, 11, 3099.	1.4	81
69	Serum adipokine levels in chronic liver diseases: Association of resistin levels with fibrosis severity. <i>Scandinavian Journal of Gastroenterology</i> , 2008, 43, 1128-1136.	0.6	78
70	Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B. <i>Journal of Hepatology</i> , 2020, 72, 1088-1096.	1.8	75
71	Significant differences of lymphocytes isolated from ascites of patients with ovarian cancer compared to blood and tumor lymphocytes. Association of CD3+CD56+ cells with platinum resistance. <i>Gynecologic Oncology</i> , 2007, 106, 75-81.	0.6	74
72	Long-term mycophenolate mofetil monotherapy in combination with calcineurin inhibitors for chronic renal dysfunction after liver transplantation. <i>Transplantation</i> , 2003, 75, 186-190.	0.5	73

#	ARTICLE	IF	CITATIONS
73	The assessment of hepatocellular carcinoma risk in patients with chronic hepatitis B under antiviral therapy. <i>Clinical and Molecular Hepatology</i> , 2016, 22, 319-326.	4.5	73
74	A Novel Immunological Assay for Hepcidin Quantification in Human Serum. <i>PLoS ONE</i> , 2009, 4, e4581.	1.1	72
75	Efficacy and safety of continuous 4-year telbivudine treatment in patients with chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2013, 20, e37-46.	1.0	72
76	Longitudinal changes in serum HBV DNA levels and predictors of progression during the natural course of HBeAg-negative chronic hepatitis B virus infection. <i>Journal of Viral Hepatitis</i> , 2008, 15, 434-441.	1.0	71
77	The European NAFLD Registry: A real-world longitudinal cohort study of nonalcoholic fatty liver disease. <i>Contemporary Clinical Trials</i> , 2020, 98, 106175.	0.8	71
78	Treatment of HBeAg-Negative Chronic Hepatitis B. <i>Seminars in Liver Disease</i> , 2003, 23, 081-088.	1.8	70
79	Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B. <i>Journal of Hepatology</i> , 2020, 73, 1037-1045.	1.8	69
80	DARING-B: Discontinuation of Effective Entecavir or Tenofovir Disoproxil Fumarate Long-Term Therapy before HBsAg Loss in Non-Cirrhotic HBeAg-Negative Chronic Hepatitis B. <i>Antiviral Therapy</i> , 2018, 23, 677-685.	0.6	68
81	Immunological Characteristics of Colitis Associated with Anti-CTLA-4 Antibody Therapy. <i>Cancer Investigation</i> , 2017, 35, 443-455.	0.6	67
82	Global real-world evidence of sofosbuvir/velpatasvir as simple, effective HCV treatment: Analysis of 5552 patients from 12 cohorts. <i>Liver International</i> , 2020, 40, 1841-1852.	1.9	66
83	Prevention of and Treatment for Hepatitis B Virus Infection After Liver Transplantation in the Nucleoside Analogues Era. <i>American Journal of Transplantation</i> , 2003, 3, 250-258.	2.6	65
84	Current management of hepatitis B virus infection before and after liver transplantation. <i>Liver International</i> , 2009, 29, 1294-1305.	1.9	65
85	Hepatitis C: The beginning of the end—key elements for successful European and national strategies to eliminate HCV in Europe. <i>Journal of Viral Hepatitis</i> , 2018, 25, 6-17.	1.0	65
86	Off-Therapy Response After Nucleos(t)ide Analogue Withdrawal in Patients With Chronic Hepatitis B: An International, Multicenter, Multiethnic Cohort (RETRACT-B Study). <i>Gastroenterology</i> , 2022, 162, 757-771.e4.	0.6	63
87	Transjugular liver biopsy in the 1990s: a 2-year audit. <i>Alimentary Pharmacology and Therapeutics</i> , 1999, 13, 603-608.	1.9	62
88	Increasing frequency of Gram-positive bacteria in spontaneous bacterial peritonitis. <i>Liver International</i> , 2005, 25, 57-61.	1.9	62
89	Metabolic syndrome is associated with severe fibrosis in chronic viral hepatitis and non-alcoholic steatohepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2008, 27, 80-89.	1.9	62
90	Hepatitis B surface antigen: Relation to hepatitis B replication parameters in HBeAg-negative chronic hepatitis B. <i>Journal of Hepatology</i> , 2011, 55, 61-68.	1.8	62

#	ARTICLE	IF	CITATIONS
91	MYCOPHENOLATE MOFETIL MONOTHERAPY IN STABLE LIVER TRANSPLANT PATIENTS WITH CYCLOSPORINE-INDUCED RENAL IMPAIRMENT. <i>Transplantation</i> , 1999, 68, 155-157.	0.5	62
92	Quantitative Analysis of Hepatitis D Virus RNA and Hepatitis B Surface Antigen Serum Levels in Chronic Delta Hepatitis Improves Treatment Monitoring. <i>Antiviral Therapy</i> , 2007, 12, 381-388.	0.6	61
93	Current management of chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2004, 19, 25-37.	1.9	60
94	Longitudinal variation in hepatitis C virus (HCV) viraemia and early course of HCV infection after liver transplantation for HCV cirrhosis: the role of different immunosuppressive regimens. <i>Gut</i> , 1999, 45, 427-434.	6.1	59
95	Range of Normal Liver Stiffness and Factors Associated With Increased Stiffness Measurements in Apparently Healthy Individuals. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 54-64.e1.	2.4	59
96	Fecal calprotectin measurement is a marker of short-term clinical outcome and presence of mucosal healing in patients with inflammatory bowel disease. <i>World Journal of Gastroenterology</i> , 2017, 23, 7387-7396.	1.4	59
97	Sofosbuvir: a novel oral agent for chronic hepatitis C. <i>Annals of Gastroenterology</i> , 2014, 27, 331-337.	0.4	59
98	Histopathology of chronic hepatitis C in relation to epidemiological factors. <i>Journal of Hepatology</i> , 1996, 24, 27-32.	1.8	58
99	Ursodeoxycholic acid for primary biliary cirrhosis: final results of a 12-year, prospective, randomized, controlled trial. <i>American Journal of Gastroenterology</i> , 2002, 97, 2063-2070.	0.2	58
100	Strategy To Characterize the Number and Type of Repeating EPIYA Phosphorylation Motifs in the Carboxyl Terminus of CagA Protein in <i>Helicobacter pylori</i> Clinical Isolates. <i>Journal of Clinical Microbiology</i> , 2007, 45, 488-495.	1.8	58
101	Serum levels of advanced glycation end-products (AGEs) and the decoy soluble receptor for AGEs (sRAGE) can identify non-alcoholic fatty liver disease in age-, sex- and BMI-matched normo-glycemic adults. <i>Metabolism: Clinical and Experimental</i> , 2018, 83, 120-127.	1.5	58
102	Correction of both prothrombin time and primary haemostasis by recombinant factor VII during therapeutic alcohol injection of hepatocellular cancer in liver cirrhosis. <i>Journal of Hepatology</i> , 1999, 31, 747-750.	1.8	56
103	Changes of HBsAg and interferon-inducible protein 10 serum levels in naive HBeAg-negative chronic hepatitis B patients under 4-year entecavir therapy. <i>Journal of Hepatology</i> , 2014, 60, 62-68.	1.8	56
104	Pseudohyperkalemia in serum: the phenomenon and its clinical magnitude. <i>Translational Research</i> , 2006, 147, 139-144.	2.4	55
105	Probability of HBsAg loss after nucleo(s)tide analogue withdrawal depends on HBV genotype and viral antigen levels. <i>Journal of Hepatology</i> , 2022, 76, 1042-1050.	1.8	54
106	Risk of hepatocellular carcinoma and extrahepatic malignancies in primary biliary cirrhosis. <i>European Journal of Gastroenterology and Hepatology</i> , 2008, 20, 5-9.	0.8	53
107	Insulin resistance and metabolic syndrome in chronic liver diseases: Old entities with new implications. <i>Scandinavian Journal of Gastroenterology</i> , 2009, 44, 6-14.	0.6	53
108	Serum hepcidin levels are related to the severity of liver histological lesions in chronic hepatitis C. <i>Journal of Viral Hepatitis</i> , 2010, 17, 800-806.	1.0	53

#	ARTICLE	IF	CITATIONS
109	Non-alcoholic fatty liver disease may develop in individuals with normal body mass index. <i>Annals of Gastroenterology</i> , 2012, 25, 45-51.	0.4	53
110	Guidance for Design and Endpoints of Clinical Trials in Chronic Hepatitis B Report From the 2019 EASL/AASLD HBV Treatment Endpoints Conference. <i>Hepatology</i> , 2020, 71, 1070-1092.	3.6	52
111	High prevalence of elevated liver enzymes in blood donors: associations with male gender and central adiposity. <i>European Journal of Gastroenterology and Hepatology</i> , 2007, 19, 281-287.	0.8	50
112	Anti-HDV IgM as a Marker of Disease Activity in Hepatitis Delta. <i>PLoS ONE</i> , 2014, 9, e101002.	1.1	50
113	Review article: nucleos(t)ide analogues in patients with chronic hepatitis B virus infection and chronic kidney disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 35-46.	1.9	49
114	Prediction of Sustained Response After Nucleo(s)tide Analogue Cessation Using HBsAg and HBcrAg Levels: A Multicenter Study (CREATE). <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e784-e793.	2.4	49
115	Seasonal Variation in Exacerbations of Ulcerative Colitis. <i>Scandinavian Journal of Gastroenterology</i> , 1993, 28, 95-96.	0.6	48
116	An artificial intelligence model to predict hepatocellular carcinoma risk in Korean and Caucasian patients with chronic hepatitis B. <i>Journal of Hepatology</i> , 2022, 76, 311-318.	1.8	48
117	Clinical predictors of poor outcomes among patients with nonvariceal upper gastrointestinal bleeding in Europe. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 33, 1225-1233.	1.9	47
118	Strategies to manage hepatitis C virus (HCV) infection disease burden volume 2. <i>Journal of Viral Hepatitis</i> , 2015, 22, 46-73.	1.0	47
119	Fulminant hepatitis due to Epstein-Barr virus infection. <i>Journal of Hepatology</i> , 1995, 23, 348-350.	1.8	46
120	Terbinafine-induced cholestatic liver disease. <i>Journal of Hepatology</i> , 1996, 24, 753-756.	1.8	46
121	Barriers to care and treatment for patients with chronic viral hepatitis in Europe: a systematic review. <i>Liver International</i> , 2014, 34, 1452-1463.	1.9	46
122	Aspartate aminotransferase to platelet ratio index for fibrosis evaluation in chronic viral hepatitis. <i>European Journal of Gastroenterology and Hepatology</i> , 2006, 18, 389-396.	0.8	45
123	Hepatic steatosis in chronic hepatitis B develops due to host metabolic factors: A comparative approach with genotype 1 chronic hepatitis C. <i>Digestive and Liver Disease</i> , 2007, 39, 936-942.	0.4	45
124	Long-term therapy with adefovir dipivoxil in hepatitis B e antigen-negative patients developing resistance to lamivudine. <i>Alimentary Pharmacology and Therapeutics</i> , 2008, 27, 266-273.	1.9	45
125	O4 PROLONGED THERAPY OF HEPATITIS DELTA FOR 96 WEEKS WITH PEGYLATED-INTERFERON-2a PLUS TENOFOVIR OR PLACEBO DOES NOT PREVENT HDV RNA RELAPSE AFTER TREATMENT: THE HIDIT-2 STUDY. <i>Journal of Hepatology</i> , 2014, 60, S2-S3.	1.8	45
126	Ombitasvir, paritaprevir, and ritonavir plus ribavirin in adults with hepatitis C virus genotype 4 infection and cirrhosis (AGATE-1): a multicentre, phase 3, randomised open-label trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2016, 1, 25-35.	3.7	45

#	ARTICLE	IF	CITATIONS
127	Prevalence and predictors of liver steatosis and fibrosis in unselected patients with HIV mono-infection. <i>Digestive and Liver Disease</i> , 2016, 48, 1471-1477.	0.4	45
128	Significance of definitions of relapse after discontinuation of oral antivirals in HBeAg-negative chronic hepatitis B. <i>Hepatology</i> , 2018, 68, 415-424.	3.6	45
129	Hepatitis B Surface Antigen Loss with Tenofovir Disoproxil Fumarate Plus Peginterferon Alfa-2a: Week 120 Analysis. <i>Digestive Diseases and Sciences</i> , 2018, 63, 3487-3497.	1.1	45
130	Smoking is associated with steatosis and severe fibrosis in chronic hepatitis C but not B. <i>Scandinavian Journal of Gastroenterology</i> , 2009, 44, 752-759.	0.6	44
131	A simulation modelling approach to evaluating alternative policies for the management of the waiting list for liver transplantation. <i>Health Care Management Science</i> , 2001, 4, 117-124.	1.5	43
132	An evaluation of emergency sclerotherapy of varices in randomized trials: looking the needle in the eye. <i>Endoscopy</i> , 2006, 38, E74-E90.	1.0	43
133	Thrombotic risk factors and liver histologic lesions in non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2009, 51, 931-938.	1.8	43
134	Clinical utility of hepatocellular carcinoma risk scores in chronic hepatitis B. <i>Liver International</i> , 2020, 40, 484-495.	1.9	42
135	Serum HBV-DNA levels in inactive hepatitis B virus carriers. <i>Gastroenterology</i> , 2002, 122, 2092-2093.	0.6	41
136	Serum apoptotic caspase activity as a marker of severity in HBeAg-negative chronic hepatitis B virus infection. <i>Gut</i> , 2007, 57, 500-506.	6.1	40
137	Serum Apoptotic Caspase Activity in Chronic Hepatitis C and Nonalcoholic Fatty Liver Disease. <i>Journal of Clinical Gastroenterology</i> , 2010, 44, e87-e95.	1.1	40
138	Hepatitis B virus reactivation in HBsAg-negative, anti-HBc-positive patients receiving immunosuppressive therapy: a systematic review. <i>Annals of Gastroenterology</i> , 2018, 31, 480-490.	0.4	40
139	Hepatic Steatosis in Genotype 4 Chronic Hepatitis C Is Mainly Because of Metabolic Factors. <i>American Journal of Gastroenterology</i> , 2007, 102, 634-641.	0.2	39
140	The Severity of Histologic Liver Lesions Is Independent of Body Mass Index in Patients With Nonalcoholic Fatty Liver Disease. <i>Journal of Clinical Gastroenterology</i> , 2013, 47, 280-286.	1.1	39
141	Hepatocellular carcinoma risk in HBsAg-negative chronic hepatitis B patients with or without cirrhosis treated with entecavir: HepNet.Greece cohort. <i>Journal of Viral Hepatitis</i> , 2015, 22, 120-127.	1.0	38
142	Predictors of hepatitis B surface antigen loss, relapse and retreatment after discontinuation of effective oral antiviral therapy in noncirrhotic HBeAg-negative chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2020, 27, 118-126.	1.0	38
143	Intrahepatic recurrence of hepatocellular carcinoma after resection: an update. <i>Clinical Journal of Gastroenterology</i> , 2021, 14, 699-713.	0.4	38
144	The impact of cereal grain consumption on the development and severity of non-alcoholic fatty liver disease. <i>European Journal of Nutrition</i> , 2014, 53, 1727-1735.	1.8	37

#	ARTICLE	IF	CITATIONS
145	Hepatocellular carcinoma in chronic hepatitis B patients under antiviral therapy. <i>World Journal of Gastroenterology</i> , 2013, 19, 8822.	1.4	37
146	Diastolic myocardial dysfunction does not affect survival in patients with cirrhosis. <i>Transplant International</i> , 2012, 25, 1174-1181.	0.8	36
147	Treatment of hepatitis B in patients with chronic kidney disease. <i>Kidney International</i> , 2013, 84, 880-885.	2.6	36
148	Predictors of response to tenofovir disoproxil fumarate plus peginterferon alfa-2a combination therapy for chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 44, 957-966.	1.9	35
149	Associations Between Lifestyle Characteristics and the Presence of Nonalcoholic Fatty Liver Disease: A Case-Control Study. <i>Metabolic Syndrome and Related Disorders</i> , 2017, 15, 72-79.	0.5	35
150	Epidemiology, course and disease burden of chronic hepatitis B virus infection. HEPNET study for chronic hepatitis B: a multicentre Greek study. <i>Journal of Viral Hepatitis</i> , 2009, 16, 195-202.	1.0	34
151	Prevalence and Impact of Upper and Lower Gastrointestinal Symptoms in the Greek Urban General Population. <i>Scandinavian Journal of Gastroenterology</i> , 2005, 40, 412-421.	0.6	33
152	A Greek survey of community prevalence and characteristics of constipation. <i>European Journal of Gastroenterology and Hepatology</i> , 2010, 22, 354-360.	0.8	33
153	Evaluation of the effectiveness of eight screening tools in detecting risk of malnutrition in cirrhotic patients: the KIRRHOS study. <i>British Journal of Nutrition</i> , 2019, 122, 1368-1376.	1.2	33
154	Role of Spleen Stiffness Measurement by 2D-Shear Wave Elastography in Ruling Out the Presence of High-Risk Varices in Cirrhotic Patients. <i>Digestive Diseases and Sciences</i> , 2019, 64, 2653-2660.	1.1	33
155	Hepatitis E virus infection in a cohort of patients with acute non-A, non-B hepatitis. <i>Journal of Hepatology</i> , 1995, 23, 668-673.	1.8	32
156	The outcome of hepatitis C virus infection after liver transplantation - is it influenced by the type of immunosuppression?. <i>Journal of Hepatology</i> , 1999, 30, 731-738.	1.8	32
157	Recurrent hepatitis C after liver transplantation. <i>Journal of Medical Virology</i> , 2000, 61, 443-454.	2.5	32
158	Impact of interferon-alpha therapy on liver fibrosis progression in patients with HBeAg-negative chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2005, 12, 199-206.	1.0	32
159	Hellenic Association for the Study of the Liver Clinical Practice Guidelines: Autoimmune hepatitis. <i>Annals of Gastroenterology</i> , 2018, 32, 1-23.	0.4	32
160	Spontaneous bacterial peritonitis in cirrhotic patients: Is prophylactic propranolol therapy beneficial?. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2006, 21, 581-587.	1.4	31
161	Public health issues of hepatitis C virus infection. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2012, 26, 371-380.	1.0	30
162	Current treatment indications and strategies in chronic hepatitis B virus infection. <i>World Journal of Gastroenterology</i> , 2008, 14, 6902.	1.4	30

#	ARTICLE	IF	CITATIONS
163	Future trends of HCV-related cirrhosis and hepatocellular carcinoma under the currently available treatments. <i>Journal of Viral Hepatitis</i> , 2005, 12, 543-550.	1.0	29
164	Recent Advances in Cirrhotic Cardiomyopathy. <i>Digestive Diseases and Sciences</i> , 2015, 60, 1141-1151.	1.1	29
165	Hepatitis B Virus DNA Integration, Chronic Infections and Hepatocellular Carcinoma. <i>Microorganisms</i> , 2021, 9, 1787.	1.6	29
166	Management of recurrent hepatitis C after liver transplantation. <i>Journal of Viral Hepatitis</i> , 2001, 8, 159-168.	1.0	28
167	New epidemiology of hepatitis delta. <i>Liver International</i> , 2020, 40, 48-53.	1.9	28
168	The case for simplifying and using absolute targets for viral hepatitis elimination goals. <i>Journal of Viral Hepatitis</i> , 2021, 28, 12-19.	1.0	28
169	Current progress in the treatment of chronic hepatitis C. <i>World Journal of Gastroenterology</i> , 2012, 18, 6060.	1.4	28
170	Recombinant human interferon alfa-2b treatment for acute non-A, non-B hepatitis. <i>Gut</i> , 1993, 34, S130-S132.	6.1	27
171	CagA and VacA Polymorphisms Are Associated with Distinct Pathological Features in Helicobacter pylori -Infected Adults with Peptic Ulcer and Non-Peptic Ulcer Disease. <i>Journal of Clinical Microbiology</i> , 2010, 48, 2237-2239.	1.8	27
172	On-treatment prediction of sustained response to peginterferon alfa-2a for HBsAg-negative chronic hepatitis B patients. <i>Liver International</i> , 2015, 35, 1540-1548.	1.9	27
173	Clinical impact of microbiome in patients with decompensated cirrhosis. <i>World Journal of Gastroenterology</i> , 2018, 24, 3813-3820.	1.4	27
174	A baseline tool for predicting response to peginterferon alfa-2a in HBsAg-positive patients with chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 547-555.	1.9	27
175	Substitution treatment or active intravenous drug use should not be contraindications for antiviral treatment in drug users with chronic hepatitis C. <i>Liver International</i> , 2010, 30, 1454-1460.	1.9	26
176	Estimating the treatment cascade of chronic hepatitis B and C in Greece using a telephone survey. <i>Journal of Viral Hepatitis</i> , 2015, 22, 409-415.	1.0	26
177	Evaluation of portal hypertension in the cirrhotic patient: hepatic vein pressure gradient and beyond. <i>Scandinavian Journal of Gastroenterology</i> , 2018, 53, 1153-1164.	0.6	26
178	Risk of HBV reactivation during therapies for HCC: A systematic review. <i>Hepatology</i> , 2022, 75, 1257-1274.	3.6	26
179	Hepatitis B virus reactivation associated with new classes of immunosuppressants and immunomodulators: A systematic review, meta-analysis, and expert opinion. <i>Journal of Hepatology</i> , 2022, 77, 1670-1689.	1.8	26
180	EASL clinical practice guidelines on the management of chronic hepatitis B: The need for liver biopsy. <i>Journal of Hepatology</i> , 2009, 51, 226-227.	1.8	25

#	ARTICLE	IF	CITATIONS
181	Associations between dietary intake and the presence of the metabolic syndrome in patients with non-alcoholic fatty liver disease. <i>Journal of Human Nutrition and Dietetics</i> , 2015, 28, 409-415.	1.3	25
182	Reliability and applicability of two-dimensional shear-wave elastography for the evaluation of liver stiffness. <i>European Journal of Gastroenterology and Hepatology</i> , 2016, 28, 1204-1209.	0.8	25
183	Peginterferon-2a (40kDa) for chronic hepatitis C. <i>Expert Opinion on Pharmacotherapy</i> , 2003, 4, 541-551.	0.9	25
184	Role of <i>Helicobacter pylori</i> eradication in aspirin or non-steroidal anti-inflammatory drug users. <i>World Journal of Gastroenterology</i> , 2005, 11, 3811.	1.4	25
185	Review of the pharmacological management of hepatitis B viral infection before and after liver transplantation. <i>World Journal of Gastroenterology</i> , 2013, 19, 9189.	1.4	25
186	Differential diagnosis of acute HBsAg positive hepatitis using IgM anti-HBc by a rapid, fully automated microparticle enzyme immunoassay. <i>Journal of Hepatology</i> , 1997, 26, 14-19.	1.8	24
187	Effect of helicobacter pylori infection on the risk of upper gastrointestinal bleeding in users of nonsteroidal anti-inflammatory drugs. <i>American Journal of Medicine</i> , 2004, 116, 601-605.	0.6	24
188	Combined HLA-DR and -DQ disparity is associated with a stable course of ulcerative colitis after liver transplantation for primary sclerosing cholangitis. <i>Liver Transplantation</i> , 2007, 13, 552-557.	1.3	24
189	Review article: novel therapeutic options for chronic hepatitis C. <i>Alimentary Pharmacology and Therapeutics</i> , 2008, 27, 866-884.	1.9	24
190	Serum HBsAg kinetics and usefulness of interferon-inducible protein 10 serum in HBsAg-negative chronic hepatitis B patients treated with tenofovir disoproxil fumarate. <i>Journal of Viral Hepatitis</i> , 2015, 22, 1079-1087.	1.0	24
191	Addressing barriers to the prevention, diagnosis and treatment of hepatitis B and C in the face of persisting fiscal constraints in Europe: report from a high level conference. <i>Journal of Viral Hepatitis</i> , 2016, 23, 1-12.	1.0	24
192	Hepatitis B: Who and when to treat?. <i>Liver International</i> , 2018, 38, 71-78.	1.9	24
193	Securing sustainable funding for viral hepatitis elimination plans. <i>Liver International</i> , 2020, 40, 260-270.	1.9	24
194	Epidemiology of nonalcoholic fatty liver disease in Europe: a systematic review and meta-analysis. <i>Annals of Gastroenterology</i> , 2021, 34, 404-414.	0.4	24
195	Blood redox status is associated with the likelihood of nonalcoholic fatty liver disease irrespectively of diet's total antioxidant capacity. <i>Nutrition Research</i> , 2015, 35, 41-48.	1.3	23
196	Treatment of chronic hepatitis C with direct-acting antivirals in patients with β -thalassaemia major and advanced liver disease. <i>British Journal of Haematology</i> , 2017, 178, 130-136.	1.2	23
197	The comprehensive outcomes of hepatitis C virus infection: A multifaceted chronic disease. <i>Journal of Viral Hepatitis</i> , 2018, 25, 6-14.	1.0	23
198	Cellular senescence and hepatitis B-related hepatocellular carcinoma: An intriguing link. <i>Liver International</i> , 2020, 40, 2917-2927.	1.9	23

#	ARTICLE	IF	CITATIONS
199	Interferon-free regimens for the treatment of hepatitis C virus in liver transplant candidates or recipients. <i>World Journal of Gastroenterology</i> , 2015, 21, 9526.	1.4	23
200	A partially overlapping treatment course with lamivudine and interferon in hepatitis B e antigen-negative chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2006, 23, 99-106.	1.9	22
201	Desmoid Tumor Presenting as Intra-Abdominal Abscess. <i>Digestive Diseases and Sciences</i> , 2006, 51, 68-69.	1.1	22
202	Randomized clinical trials towards a single-visit cure for chronic hepatitis C: Oral GSK2878175 and injectable RG4101 in chronic hepatitis C patients and long-acting injectable GSK2878175 in healthy participants. <i>Journal of Viral Hepatitis</i> , 2020, 27, 699-708.	1.0	22
203	Liver transplantation and inflammatory bowel disease. <i>Journal of Hepatology</i> , 1998, 28, 1070-1076.	1.8	21
204	Serum HCV RNA levels and HCV genotype do not affect insulin resistance in nondiabetic patients with chronic hepatitis C: a multicentre study. <i>Alimentary Pharmacology and Therapeutics</i> , 2009, 30, 947-954.	1.9	21
205	DARING-B: discontinuation of effective entecavir or tenofovir therapy in non-cirrhotic HBeAg-negative chronic hepatitis B patients: a prospective Greek study. <i>Journal of Hepatology</i> , 2017, 66, S26.	1.8	21
206	Early prediction of successful alpha-interferon therapy of chronic hepatitis C by core-IgM antibodies to hepatitis C virus. <i>Journal of Hepatology</i> , 1994, 20, 305-306.	1.8	20
207	Adefovir dipivoxil in the treatment of chronic hepatitis B virus infection. <i>Expert Review of Anti-Infective Therapy</i> , 2004, 2, 475-483.	2.0	20
208	Analytical and clinical sensitivity of the Procleix Ultrio HIV-1/HCV/HBV assay in samples with a low viral load. <i>Vox Sanguinis</i> , 2007, 92, 8-14.	0.7	20
209	Natural course of treated and untreated chronic HCV infection: results of the nationwide <i>Hepnet</i> <i>Greece</i> cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , 2009, 29, 1121-1130.	1.9	20
210	Left ventricle enlargement and increased systolic velocity in the mitral valve are indirect markers of the hepatopulmonary syndrome. <i>Liver International</i> , 2011, 31, 1388-1394.	1.9	20
211	Increased serum miR-193a-5p during non-alcoholic fatty liver disease progression: Diagnostic and mechanistic relevance. <i>JHEP Reports</i> , 2022, 4, 100409.	2.6	20
212	Letters to the Editor. <i>American Journal of Gastroenterology</i> , 2007, 102, 201-221.	0.2	19
213	Resistance issues in treating chronic hepatitis B. <i>Future Microbiology</i> , 2008, 3, 525-538.	1.0	19
214	HBV: Do I treat my immunotolerant patients?. <i>Liver International</i> , 2016, 36, 93-99.	1.9	19
215	Primary aortojejunal fistula due to foreign body: a rare cause of gastrointestinal bleeding. <i>European Journal of Gastroenterology and Hepatology</i> , 2002, 14, 797-800.	0.8	18
216	Peginterferon- α 2a(40 kDa) for chronic hepatitis C. <i>Expert Opinion on Pharmacotherapy</i> , 2003, 4, 541-551.	0.9	18

#	ARTICLE	IF	CITATIONS
217	Quantitative Detection of the M204V Hepatitis B Virus Minor Variants by Amplification Refractory Mutation System Real-Time PCR Combined with Molecular Beacon Technology. <i>Journal of Clinical Microbiology</i> , 2009, 47, 2544-2550.	1.8	18
218	The usefulness of transient elastography in the assessment of patients with HBsAg-negative chronic hepatitis B virus infection. <i>Journal of Viral Hepatitis</i> , 2014, 21, 517-524.	1.0	18
219	Patient-reported outcomes in patients chronic viral hepatitis without cirrhosis: The impact of hepatitis B and C viral replication. <i>Liver International</i> , 2019, 39, 1837-1844.	1.9	18
220	GS-02-Efficacy of GKT831 in patients with primary biliary cholangitis and inadequate response to ursodeoxycholic acid: Interim efficacy results of a phase 2 clinical trial. <i>Journal of Hepatology</i> , 2019, 70, e1-e2.	1.8	18
221	Can we stop nucleoside analogues before HBsAg loss?. <i>Journal of Viral Hepatitis</i> , 2019, 26, 936-941.	1.0	18
222	Risk Scores for Hepatocellular Carcinoma in Chronic Hepatitis B: A Promise for Precision Medicine. <i>Hepatology</i> , 2020, 72, 2197-2205.	3.6	18
223	Residual low HDV viraemia is associated HDV RNA relapse after PEGIFNα-based antiviral treatment of hepatitis delta: Results from the HIDIT study. <i>Liver International</i> , 2021, 41, 295-299.	1.9	18
224	Characteristics of rectosigmoid adenomas as predictors of synchronous advanced proximal colon neoplasms. <i>American Journal of Gastroenterology</i> , 1996, 91, 1809-13.	0.2	18
225	Significance of IgM anti-HCVcore level in chronic hepatitis C. <i>Journal of Hepatology</i> , 1997, 27, 36-41.	1.8	17
226	Variability in the Management of Nonvariceal Upper Gastrointestinal Bleeding in Europe: An Observational Study. <i>Advances in Therapy</i> , 2012, 29, 1026-1036.	1.3	17
227	Cost-effectiveness of noninvasive liver fibrosis tests for treatment decisions in patients with chronic hepatitis B in the UK: systematic review and economic evaluation. <i>Journal of Viral Hepatitis</i> , 2016, 23, 139-149.	1.0	17
228	Immunological biomarkers as indicators for outcome after discontinuation of nucleos(t)ide analogue therapy in patients with HBsAg-negative chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2019, 26, 697-709.	1.0	17
229	Comparative Study of Mutations in Single Nucleotide Polymorphism Loci of KRAS and BRAF Genes in Patients Who Underwent Screening Colonoscopy, With and Without Premalignant Intestinal Polyps. <i>Anticancer Research</i> , 2017, 37, 651-658.	0.5	17
230	Chronic hepatitis C and no response to antiviral therapy: potential current and future therapeutic options. <i>Journal of Viral Hepatitis</i> , 2004, 11, 287-296.	1.0	16
231	The burden and recent epidemiological changes of the main chronic liver diseases in a Greek referral tertiary centre. <i>European Journal of Gastroenterology and Hepatology</i> , 2010, 22, 172-179.	0.8	16
232	A “healthy diet” optimal sleep-lifestyle pattern is inversely associated with liver stiffness and insulin resistance in patients with nonalcoholic fatty liver disease. <i>Applied Physiology, Nutrition and Metabolism</i> , 2017, 42, 250-256.	0.9	16
233	Interferon-free regimens in patients with hepatitis C infection and renal dysfunction or kidney transplantation. <i>World Journal of Hepatology</i> , 2017, 9, 180.	0.8	16
234	Emerging Diagnostic Tools to Decide When to Discontinue Nucleos(t)ide Analogues in Chronic Hepatitis B. <i>Cells</i> , 2020, 9, 493.	1.8	16

#	ARTICLE	IF	CITATIONS
235	Systemic absorption of 5-aminosalicylic acid in patients with inactive ulcerative colitis treated with olsalazine and mesalazine. <i>European Journal of Gastroenterology and Hepatology</i> , 1996, 8, 1083-1088.	0.8	15
236	911 PROLONGED EFFICACY AND SAFETY OF 3 YEARS OF CONTINUOUS TELBIVUDINE TREATMENT IN POOLED DATA FROM GLOBE AND 015 STUDIES IN CHRONIC HEPATITIS B PATIENTS. <i>Journal of Hepatology</i> , 2009, 50, S331.	1.8	15
237	Why do I treat HBeAg-negative chronic hepatitis B patients with nucleos(t)ide analogues?. <i>Liver International</i> , 2013, 33, 151-156.	1.9	15
238	The impact of newer nucleos(t)ide analogues on patients with hepatitis B decompensated cirrhosis. <i>Annals of Gastroenterology</i> , 2015, 28, 109-117.	0.4	15
239	Changes in serum transforming growth factor- β 1 levels in chronic hepatitis C patients under antiviral therapy. <i>Annals of Gastroenterology</i> , 2016, 29, 79-84.	0.4	15
240	Comparative efficacy of a high or low dose of interferon alpha 2b in chronic hepatitis C: a randomized controlled trial. <i>American Journal of Gastroenterology</i> , 1996, 91, 1734-8.	0.2	15
241	Recommendations of the ESGE Workshop on Informed Consent for Digestive Endoscopy. <i>Endoscopy</i> , 2003, 35, 772-774.	1.0	14
242	Prevalence of glucose intolerance in patients with chronic hepatitis B or C: a prospective case-control study. <i>Journal of Viral Hepatitis</i> , 2009, 16, 430-436.	1.0	14
243	Ultrasensitive Amplification Refractory Mutation System Real-Time PCR (ARMS RT-PCR) Assay for Detection of Minority Hepatitis B Virus-Resistant Strains in the Era of Personalized Medicine. <i>Journal of Clinical Microbiology</i> , 2013, 51, 2893-2900.	1.8	14
244	Lower risk of hepatocellular carcinoma with tenofovir than entecavir treatment in subsets of chronic hepatitis B patients: an updated meta-analysis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2022, 37, 782-794.	1.4	14
245	Emerging treatments in chronic hepatitis B. <i>Expert Opinion on Emerging Drugs</i> , 2004, 9, 207-221.	1.0	13
246	Survivin Expression in Colorectal Carcinomas: Correlations with Clinicopathological Parameters and Survival. <i>Digestive Diseases and Sciences</i> , 2010, 55, 2958-2964.	1.1	13
247	Is there any progress in the treatment of non-alcoholic fatty liver disease?. <i>World Journal of Gastrointestinal Pharmacology and Therapeutics</i> , 2011, 2, 1.	0.6	13
248	Treatment of HBeAg-negative chronic hepatitis B patients with nucleos(t)ide analogues. <i>Liver International</i> , 2011, 31, 95-103.	1.9	13
249	Long-term adefovir plus lamivudine therapy does not decrease creatinine clearance in HBeAg-negative chronic hepatitis B patients. <i>Liver International</i> , 2011, 31, 1525-1532.	1.9	13
250	HBeAg-negative chronic hepatitis B: why do I treat my patients with pegylated interferon- α ?. <i>Liver International</i> , 2014, 34, 127-132.	1.9	13
251	Hepatitis B s antigen kinetics during treatment with nucleos(t)ides analogues in patients with hepatitis B e antigen-negative chronic hepatitis B. <i>Liver International</i> , 2017, 37, 1642-1650.	1.9	13
252	Economic evaluation of the hepatitis C elimination strategy in Greece in the era of affordable direct-acting antivirals. <i>World Journal of Gastroenterology</i> , 2019, 25, 1327-1340.	1.4	13

#	ARTICLE	IF	CITATIONS
253	The interferon receptor 1 promoter polymorphisms affect the outcome of Caucasians with HBeAg-negative chronic HBV infection. <i>Liver International</i> , 2015, 35, 2506-2513.	1.9	12
254	Optimal therapy of chronic hepatitis B: how do I treat HBeAg-positive patients?. <i>Liver International</i> , 2015, 35, 100-106.	1.9	12
255	Long-term Effects of Treatment for Chronic HBV Infection on Patient-Reported Outcomes. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1641-1642.e1.	2.4	12
256	Is hepatitis delta underestimated?. <i>Liver International</i> , 2021, 41, 38-44.	1.9	12
257	Fulminant hepatitis due to Epstein-Barr virus infection. <i>Journal of Hepatology</i> , 1995, 23, 348-50.	1.8	12
258	Ursodeoxycholic acid and histological progression in primary biliary cirrhosis. <i>Journal of Hepatology</i> , 2003, 39, 1094-1095.	1.8	11
259	Clinicopathological features and natural history of acute sporadic non-A-E hepatitis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2008, 23, 1208-1215.	1.4	11
260	GS-03-Global real world evidence of sofosbuvir/velpatasvir as a simple, effective regimen for the treatment of chronic hepatitis C patients: Integrated analysis of 12 clinical practice cohorts. <i>Journal of Hepatology</i> , 2019, 70, e2-e3.	1.8	11
261	Frequency and predictors of no treatment in anti-hepatitis C virus-positive patients at tertiary liver centers in Greece. <i>European Journal of Gastroenterology and Hepatology</i> , 2013, 25, 587-593.	0.8	10
262	P1075 PAGE-B: RISK SCORE FOR HEPATOCELLULAR CARCINOMA (HCC) DEVELOPMENT IN CAUCASIAN CHRONIC HEPATITIS B (CHB) PATIENTS RECEIVING ENTECAVIR (ETV) OR TENOFOVIR (TDF). <i>Journal of Hepatology</i> , 2014, 60, S435.	1.8	10
263	O117 : Predictors of clinical response: Results from a large, randomized controlled study with tenofovir disoproxil fumarate (TDF) plus peginterferon alfa-2A (PEG) combination for chronic hepatitis B (CHB). <i>Journal of Hepatology</i> , 2015, 62, S251-S252.	1.8	10
264	Is elimination of HCV possible in a country with low diagnostic rate and moderate HCV prevalence?: The case of Greece. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 466-472.	1.4	10
265	Long-term Patient-Centered Outcomes in Cirrhotic Patients With Chronic Hepatitis C After Achieving Sustained Virologic Response. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 438-446.	2.4	10
266	Nonalcoholic fatty liver disease: The role of quercetin and its therapeutic implications. <i>Saudi Journal of Gastroenterology</i> , 2021, 27, 319-330.	0.5	10
267	Naftidrofuryl-Induced Liver Injury. <i>American Journal of Gastroenterology</i> , 2003, 98, 1448-1450.	0.2	9
268	Prophylactic and therapeutic use of recombinant activated factor VII in patients with cirrhosis and coagulation impairment. <i>Digestive and Liver Disease</i> , 2007, 39, 490-494.	0.4	9
269	Smoking is associated with histological severity in nonalcoholic steatohepatitis. <i>Hepatology</i> , 2010, 52, 1522-1523.	3.6	9
270	Hepatitis B and C coinfection in a real-life setting: viral interactions and treatment issues. <i>Annals of Gastroenterology</i> , 2018, 31, 365-370.	0.4	9

#	ARTICLE	IF	CITATIONS
271	Is Tenofovir Superior to Entecavir in Reducing the Risk of Hepatocellular Carcinoma in Chronic Hepatitis B? The Controversy Continues. <i>Gastroenterology</i> , 2020, 158, 42-44.	0.6	9
272	Impact of HBeAg on Hepatocellular Carcinoma Risk During Oral Antiviral Treatment in Patients With Chronic Hepatitis B. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 1343-1353.e16.	2.4	9
273	Hepatocellular carcinoma: The virus or the liver?. <i>Liver International</i> , 2023, 43, 22-30.	1.9	9
274	Hepatocellular carcinoma after treatment cessation in non-cirrhotic HBeAg-negative chronic hepatitis B: A multicentre cohort study. <i>Liver International</i> , 2022, 42, 541-550.	1.9	9
275	Acute pancreatitis associated with <i>Salmonella enteritidis</i> . <i>American Journal of Gastroenterology</i> , 2001, 96, 3450-3451.	0.2	8
276	Treatment of HBeAg negative chronic hepatitis B with new drugs (adefovir and others). <i>Journal of Hepatology</i> , 2003, 39, 172-176.	1.8	8
277	Hepatitis B virus treatment: Which patients can have treatment deferred?. <i>Clinical Liver Disease</i> , 2013, 2, 15-17.	1.0	8
278	Liver Function Breath Tests for Differentiation of Steatohepatitis From Simple Fatty Liver in Patients With Nonalcoholic Fatty Liver Disease. <i>Journal of Clinical Gastroenterology</i> , 2014, 48, 59-65.	1.1	8
279	Increased abdominal fat levels measured by bioelectrical impedance are associated with histological lesions of nonalcoholic steatohepatitis. <i>European Journal of Gastroenterology and Hepatology</i> , 2015, 27, 907-913.	0.8	8
280	Common ABCB1 polymorphisms in Greek patients with chronic hepatitis C infection: A comparison with hyperlipidemic patients and the general population. <i>Pharmacological Reports</i> , 2016, 68, 476-482.	1.5	8
281	Impact of Interferon- γ Receptor-1 Promoter Polymorphisms on the Transcriptome of the Hepatitis B Virus-Associated Hepatocellular Carcinoma. <i>Frontiers in Immunology</i> , 2018, 9, 777.	2.2	8
282	High prevalence of asymptomatic peptic ulcers diagnosed during screening endoscopy in patients with cirrhosis. <i>Annals of Gastroenterology</i> , 2019, 32, 451-456.	0.4	8
283	Current status of hepatitis delta. <i>Current Opinion in Pharmacology</i> , 2021, 58, 62-67.	1.7	8
284	High Sustained Virologic Response Rates of Glecaprevir/Pibrentasvir in Patients With Dosing Interruption or Suboptimal Adherence. <i>American Journal of Gastroenterology</i> , 2021, 116, 1896-1904.	0.2	8
285	The burden and management of anemia in Greek patients with inflammatory bowel disease: a retrospective, multicenter, observational study. <i>BMC Gastroenterology</i> , 2021, 21, 269.	0.8	8
286	The upward trend in the immunotherapy utilization for hepatobiliary cancers. <i>Hepatobiliary Surgery and Nutrition</i> , 2021, 10, 692-695.	0.7	8
287	Validation of cutoffs for skeletal muscle mass index based on computed tomography analysis against dual energy X-ray absorptiometry in patients with cirrhosis: the KIRRHOS study. <i>Annals of Gastroenterology</i> , 2019, 33, 80-86.	0.4	8
288	Factors associated with severity and disease progression in chronic hepatitis C. <i>Hepato-Gastroenterology</i> , 1998, 45, 1678-83.	0.5	8

#	ARTICLE	IF	CITATIONS
289	The Bcl-2/Bax system and apoptosis in ulcerative colitis. <i>Hepato-Gastroenterology</i> , 2007, 54, 1085-8.	0.5	8
290	Simultaneous Diagnosis of Ulcerative Jejunoileitis and Coeliac Disease in an Elderly Man. <i>Digestion</i> , 2006, 73, 20-24.	1.2	7
291	First appearance of Crohn's disease following infliximab treatment for spondylarthropathy. <i>Scandinavian Journal of Gastroenterology</i> , 2007, 42, 784-785.	0.6	7
292	Potential Role of Apoptosis and Apoptotic Regulatory Proteins in Colorectal Neoplasia: Correlations with Clinico-Pathological Parameters and Survival. <i>Digestive Diseases and Sciences</i> , 2008, 53, 451-460.	1.1	7
293	A hepatitis C outbreak preceded the HIV outbreak among persons who inject drugs in Athens, Greece: Insights from a mathematical modelling study. <i>Journal of Viral Hepatitis</i> , 2019, 26, 1311-1317.	1.0	7
294	Aiming towards hepatitis C virus elimination in Greece. <i>Annals of Gastroenterology</i> , 2019, 32, 321-329.	0.4	7
295	An Evaluation of Diagnosis-Related Group (DRG) Implementation Focused on Cancer DRGs in Greek Public Hospitals. <i>PharmacoEconomics - Open</i> , 2020, 4, 61-69.	0.9	7
296	Preoperative Evaluation of Coronary Artery Disease in Liver Transplant Candidates: Many Unanswered Questions in Clinical Practice. <i>Diagnostics</i> , 2021, 11, 75.	1.3	7
297	Antiviral prophylaxis against hepatitis B recurrence after liver transplantation: Current concepts. <i>Liver International</i> , 2021, 41, 1448-1461.	1.9	7
298	SARS-CoV-2 Molecular Transmission Clusters and Containment Measures in Ten European Regions during the First Pandemic Wave. <i>Life</i> , 2021, 11, 219.	1.1	7
299	Comparative Utility of Transient and 2D Shear Wave Elastography for the Assessment of Liver Fibrosis in Clinical Practice. <i>Journal of Digital Imaging</i> , 2021, 34, 1342-1348.	1.6	7
300	A Proposed Etiology for an Aberrant Response to Enteric Adenovirus Infection in Previously SARS-CoV-2-Infected Children With Acute Hepatitis. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2022, 11, 352-353.	0.6	7
301	Significance of serum HBV RNA in non-cirrhotic HBeAg-negative chronic hepatitis B patients who discontinue effective antiviral therapy. <i>Journal of Viral Hepatitis</i> , 2022, 29, 948-957.	1.0	7
302	Ursodeoxycholic-acid for primary biliary cirrhosis: Final results of A12-year prospective, randomised, controlled trial. <i>Journal of Hepatology</i> , 2000, 32, 40.	1.8	6
303	Significance of hepatitis B viremia levels determined by a quantitative polymerase chain reaction assay in patients with hepatitis B e antigen-negative chronic hepatitis B virus infection. <i>American Journal of Gastroenterology</i> , 2003, 98, 2261-2267.	0.2	6
304	Changes of serum levels of keratin-18 fragments in hepatitis B e antigen-negative chronic hepatitis B patients under oral antiviral therapy. <i>Antiviral Therapy</i> , 2011, 16, 505-514.	0.6	6
305	Cirrhosis but not neutropenia is associated with the development of infection in patients with chronic hepatitis C undergoing treatment with pegylated interferon-alpha and ribavirin. <i>Journal of Viral Hepatitis</i> , 2014, 21, 624-632.	1.0	6
306	Elevated Serum Levels of the Antiapoptotic Protein Decoy-Receptor 3 Are Associated with Advanced Liver Disease. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2016, 2016, 1-8.	0.8	6

#	ARTICLE	IF	CITATIONS
307	Rg-101 in Combination With 4 Weeks of Oral Direct Acting Antiviral Therapy Achieves High Virologic Response Rates in Treatment Naïve Genotype 1 and 4 Chronic Hepatitis C Patients: Interim Results from a Randomised, Multicenter, Phase 2 Study. <i>Journal of Hepatology</i> , 2016, 64, S159.	1.8	6
308	One-year Fibrosis-4 index helps identify minimal HCC risk in non-cirrhotic chronic hepatitis B patients with antiviral treatment. <i>Hepatology International</i> , 2021, 15, 105-113.	1.9	6
309	Response to Anti-Î±4Î²7 Blockade in Patients With Ulcerative Colitis Is Associated With Distinct Mucosal Gene Expression Profiles at Baseline. <i>Inflammatory Bowel Diseases</i> , 2022, 28, 87-95.	0.9	6
310	Significance of Circulating Cell-Free DNA Species in Non-Alcoholic Fatty Liver Disease. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8849.	1.8	6
311	The significance of platelet microparticles in patients with chronic hepatitis C and their association with antiviral treatment and smoking. <i>Annals of Gastroenterology</i> , 2016, 29, 201-7.	0.4	6
312	Efficacy and safety profile of boceprevir- or telaprevir-based triple therapy or dual peginterferon alfa-2a or alfa-2b plus ribavirin therapy in chronic hepatitis C: the real-world PegBase observational study. <i>Annals of Gastroenterology</i> , 2017, 30, 327-343.	0.4	6
313	Long-term clinical outcome of HBsAg-negative chronic hepatitis B patients who discontinued nucleos(t)ide analogues. <i>Liver International</i> , 2021, 41, 48-57.	1.9	6
314	<scp>HERACLISâ€TAF</scp>: a multiâ€centre prospective cohort study on 2â€year safety and efficacy of tenofovir alafenamide in patients with chronic hepatitis B with renal and/or bone disorders or risks. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 56, 702-712.	1.9	6
315	Pericarditis and possible antiphospholipid syndrome on primary biliary cirrhosis. <i>Annals of Hepatology</i> , 2004, 3, 167-168.	0.6	5
316	Recent peginterferon and ribavirin combination trials. <i>Current Hepatitis Reports</i> , 2004, 3, 30-37.	0.3	5
317	[644] HEPATIC STEATOSIS PREDICTS OUTCOME OF CHRONIC HEPATITIS C THERAPY WITH PEG-INTERFERON PLUS RIBAVIRIN, INDEPENDENTLY OF GENOTYPE OR BMI BUT IN CORRELATION TO INSULIN RESISTANCE (HOMA-IR). <i>Journal of Hepatology</i> , 2007, 46, S243.	1.8	5
318	Serum hepatitis B virus-DNA cutoff levels in hepatitis B e antigenâ€negative chronic hepatitis B virus infection. <i>Hepatology</i> , 2007, 46, 606-607.	3.6	5
319	Role of genetic polymorphisms in the progression of liver fibrosis in chronic hepatitis C virus infection. <i>Liver International</i> , 2008, 28, 764-766.	1.9	5
320	Patient Management and Clinical Decision Making in HBV â€ Aims of Therapy and What we can Achieve. <i>Antiviral Therapy</i> , 2010, 15, 45-51.	0.6	5
321	Serum markers of hepatocyte apoptosis: Current terminology and predictability in clinical practice. <i>Hepatology</i> , 2010, 51, 717-718.	3.6	5
322	766 HEPATOCELLULAR CARCINOMA (HCC) RISK IN HBsAg-NEGATIVE CHRONIC HEPATITIS B (CHBeâˆ) WITH OR WITHOUT CIRRHOSIS TREATED WITH ENTECAVIR: RESULTS OF THE NATIONWIDE HepNet.Greece COHORT STUDY. <i>Journal of Hepatology</i> , 2013, 58, S312.	1.8	5
323	Four years of tenofovir monotherapy for NUC naïve field practice European patients suppresses HBV replication in most patients with a favorable renal safety profile but does not prevent HCC in patients with or without cirrhosis. <i>Digestive and Liver Disease</i> , 2014, 46, e14.	0.4	5
324	A transient early HBVâ€DNA increase during PEGâ€IFNÎ± therapy of hepatitis D indicates loss of infected cells and is associated with HDVâ€RNA and HBsAg reduction. <i>Journal of Viral Hepatitis</i> , 2021, 28, 410-419.	1.0	5

#	ARTICLE	IF	CITATIONS
325	Predictive performance of newer Asian hepatocellular carcinoma risk scores in treated Caucasians with chronic hepatitis B. <i>JHEP Reports</i> , 2021, 3, 100290.	2.6	5
326	Phase IIa safety and efficacy of milciclib, a pan-cyclin dependent kinase inhibitor, in unresectable, sorafenib-refractory or -intolerant hepatocellular carcinoma patients.. <i>Journal of Clinical Oncology</i> , 2020, 38, e16711-e16711.	0.8	5
327	Serum levels of vascular endothelial growth factor in non-alcoholic fatty liver disease. <i>Annals of Gastroenterology</i> , 2016, 30, 209-216.	0.4	5
328	Design and Development of a Viral Hepatitis and HIV Infection Screening Program (Hprolipsis) for the General, Greek Roma, and Migrant Populations of Greece: Protocol for Three Cross-Sectional Health Examination Surveys. <i>JMIR Research Protocols</i> , 2020, 9, e13578.	0.5	5
329	Serum zonulin levels in patients with liver cirrhosis: Prognostic implications. <i>World Journal of Hepatology</i> , 2021, 13, 1394-1404.	0.8	5
330	Serum hepatitis B virus RNA detectability, composition and clinical significance in patients with ab initio hepatitis B e antigen negative chronic hepatitis B. <i>Virology Journal</i> , 2022, 19, 22.	1.4	5
331	Seasonal variation in exacerbations of ulcerative colitis. <i>Hepato-Gastroenterology</i> , 1997, 44, 1334-8.	0.5	5
332	Epidemiology and treatment of hepatitis E in the liver transplantation setting: A literature review. <i>Journal of Viral Hepatitis</i> , 2022, 29, 698-718.	1.0	5
333	Ethics Related to Liver Biopsies and Antiviral Therapies in Chronic Viral Hepatitis. <i>Digestive Diseases</i> , 2008, 26, 59-65.	0.8	4
334	525 TENOFOVIR MONOTHERAPY FOR NAIVE PATIENTS WITH CHRONIC HEPATITIS B: A MULTICENTER EUROPEAN STUDY IN CLINICAL PRACTICE IN 302 PATIENTS FOLLOWED FOR 30 MONTHS. <i>Journal of Hepatology</i> , 2012, 56, S208.	1.8	4
335	P0641 : Excellent 5-year survival in caucasian chronic hepatitis B (CHB) patients with or without cirrhosis under long-term entecavir (ETV) or tenofovir (TDF) therapy and the impact of hepatocellular carcinoma (HCC). <i>Journal of Hepatology</i> , 2015, 62, S559-S560.	1.8	4
336	Efficacy of prophylactic antiviral therapy and outcomes in HBsAg-negative, anti-HBc-positive patients receiving chemotherapy. <i>European Journal of Gastroenterology and Hepatology</i> , 2017, 29, 56-60.	0.8	4
337	Persistence and adherence to nucleos(t)ide analogues in chronic hepatitis B: a multicenter cohort study. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, 32, 635-641.	0.8	4
338	Efficacy and safety of new direct-acting antivirals in kidney transplant recipients with chronic hepatitis C: a single-center study. <i>Annals of Gastroenterology</i> , 2020, 33, 285-292.	0.4	4
339	Circulating cell-free DNA species affect the risk of hepatocellular carcinoma in treated chronic hepatitis B patients. <i>Journal of Viral Hepatitis</i> , 2021, 28, 464-474.	1.0	4
340	Predictors of Response to Vedolizumab in Patients with Ulcerative Colitis: Results from the Greek VEDO-IBD Cohort. <i>Digestive Diseases and Sciences</i> , 2022, 67, 1007-1017.	1.1	4
341	Assessment of dietary habits and the adequacy of dietary intake of patients with cirrhosis-the KIRRHOS study. <i>Clinical Nutrition</i> , 2021, 40, 3992-3998.	2.3	4
342	A genotype-specific baseline score predicts post-treatment response to peginterferon alfa-2a in Hepatitis B e antigen-negative chronic hepatitis B. <i>Annals of Gastroenterology</i> , 2018, 31, 712-721.	0.4	4

#	ARTICLE	IF	CITATIONS
343	Association of cardiovascular factors in diabetic patients with non-alcoholic fatty liver disease. <i>Hormones</i> , 2021, , 1.	0.9	4
344	The significance of C-reactive protein to albumin ratio in patients with decompensated cirrhosis. <i>Annals of Gastroenterology</i> , 2020, 33, 667-674.	0.4	4
345	Monitoring and comorbidities in patients with chronic hepatitis B currently treated with nucleos(t)ide analogs. <i>Annals of Gastroenterology</i> , 2020, 34, 73-79.	0.4	4
346	Biochemical and virological response of chronic hepatitis C after treatment with interferon-alpha for 6 or 12 months: predictors of sustained remission. <i>European Journal of Gastroenterology and Hepatology</i> , 1996, 8, 469-75.	0.8	4
347	Treatment of acute non-A, non-B hepatitis with interferon alpha-2b. <i>Infection</i> , 1992, 20, 242-242.	2.3	3
348	Prevalence of antibodies to hepatitis C virus in Greek patients with chronic liver disease. <i>Journal of Hepatology</i> , 1994, 20, 311.	1.8	3
349	p53 and bcl-2 Protein Expression in Rectosigmoid Adenomas. <i>American Journal of Gastroenterology</i> , 1998, 93, 1136-1140.	0.2	3
350	230 SERUM HEPcidIN LEVELS DEPEND ON AETIOLOGY BUT NOT SEVERITY OF CIRRHOSIS. <i>Journal of Hepatology</i> , 2009, 50, S93.	1.8	3
351	714 HBSAG LEVELS DURING THE FIRST 24 WEEKS OF PEGINTERFERON ALFA-2A [40KD] (PEGASYS) TREATMENT IN PATIENTS WITH HBEAG-NEGATIVE CHRONIC HEPATITIS B: THE PERSEAS COHORT. <i>Journal of Hepatology</i> , 2011, 54, S286-S287.	1.8	3
352	Endoscopic and Histological Findings and Helicobacter pylori Status in Patients With Reflux and/or Dyspeptic Symptoms. <i>Gastroenterology Nursing</i> , 2014, 37, 431-438.	0.2	3
353	A Genotype-Specific Baseline Score to Predict Response at 48 Weeks Post-Treatment to Peginterferon Alfa-2a in Patients with HBeAg-Negative Chronic Hepatitis B. <i>Journal of Hepatology</i> , 2016, 64, S599-S600.	1.8	3
354	Adherence to follow-up and treatment recommendations in Greek and immigrant patients with chronic hepatitis B in Greece. <i>European Journal of Gastroenterology and Hepatology</i> , 2017, 29, 264-270.	0.8	3
355	Proton pump inhibitor and selective serotonin reuptake inhibitor therapy for the management of noncardiac chest pain. <i>European Journal of Gastroenterology and Hepatology</i> , 2017, 29, 1054-1058.	0.8	3
356	Treatment cascade of hepatitis B and C in general, migrant and Roma populations. <i>Journal of Hepatology</i> , 2017, 66, S71-S72.	1.8	3
357	Rates and predictors of HBsAg loss after discontinuation of effective long-term Entecavir or Tenofovir therapy in noncirrhotic HBeAg-negative chronic hepatitis B patients: Results from the DARING-B prospective Greek study. <i>Journal of Hepatology</i> , 2018, 68, S88-S89.	1.8	3
358	Liver transplantation using hepatitis B core positive grafts: Which is the optimal antiviral prophylaxis?. <i>Journal of Hepatology</i> , 2019, 71, 635-636.	1.8	3
359	Genetic variation in <i>FCER1A</i> predicts peginterferon alfa-2a-induced hepatitis B surface antigen clearance in East Asian patients with chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2019, 26, 1040-1049.	1.0	3
360	New concepts in the finite oral antiviral therapy in HBeAg-negative chronic hepatitis B. <i>Journal of Hepatology</i> , 2021, 75, 1495-1496.	1.8	3

#	ARTICLE	IF	CITATIONS
361	Prioritization for interferon-free regimens and potential drug interactions of current direct-acting anti-hepatitis C agents in routine clinical practice. <i>Annals of Gastroenterology</i> , 2017, 30, 542-549.	0.4	3
362	Significance of the C-caffeine breath test for patients with cirrhosis. <i>Annals of Gastroenterology</i> , 2014, 27, 53-59.	0.4	3
363	The changing epidemiology of hepatocellular carcinoma in Greece. <i>Annals of Gastroenterology</i> , 2021, 35, 88-94.	0.4	3
364	Acute delta hepatitis in Greek parenteral drug abusers. <i>Progress in Clinical and Biological Research</i> , 1993, 382, 221-7.	0.2	3
365	Predictors of the early development of advanced metachronous colon adenomas. <i>Hepato-Gastroenterology</i> , 1997, 44, 533-8.	0.5	3
366	Prevalence of antibodies to hepatitis C virus in greek patients with chronic liver disease. <i>Journal of Hepatology</i> , 1994, 20, 843.	1.8	2
367	Indefinite Dysplasia in Ulcerative Colitis Has Little Clinical Significance and Is Not Associated With p53 Protein Accumulation. <i>American Journal of Gastroenterology</i> , 1998, 93, 285-286.	0.2	2
368	p53 protein accumulation and colonic adenoma recurrence. <i>European Journal of Gastroenterology and Hepatology</i> , 1999, 11, 547-552.	0.8	2
369	Course of virologic breakthroughs under lamivudine therapy in patients with precore mutant HBV related liver disease. <i>Gastroenterology</i> , 2001, 120, A385.	0.6	2
370	Hepatobiliary and pancreatic: Spontaneous splenorenal shunts in portal hypertension. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2006, 21, 1214-1214.	1.4	2
371	[481] HBeAg-NEGATIVE CHRONIC HEPATITIS B (CHBe-) IN CHRONIC HBV PATIENTS WITH SERUM HBV-DNA LEVELS BELOW 2,000 IU/mL. <i>Journal of Hepatology</i> , 2007, 46, S183.	1.8	2
372	Adipokines and insulin resistance in chronic hepatitis C. <i>Hepatology</i> , 2007, 46, 2050-2051.	3.6	2
373	Reply:. <i>Hepatology</i> , 2009, 49, 705-706.	3.6	2
374	Elastography for Hepatic Fibrosis Severity in Chronic Hepatitis B or C. <i>Case Reports in Gastroenterology</i> , 2011, 5, 63-72.	0.3	2
375	350 TRANSIENT ELASTOGRAPHY (FIBROSCAN) IN PATIENTS WITH CHRONIC HEPATITIS B IN EVERYDAY CLINICAL PRACTICE. <i>Journal of Hepatology</i> , 2011, 54, S140-S141.	1.8	2
376	852 NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) MAY DEVELOP IN PATIENTS WITH NORMAL BODY MASS INDEX (BMI). <i>Journal of Hepatology</i> , 2011, 54, S340.	1.8	2
377	Significance of liver histology in HBsAg-positive, IgM anti-HBc-negative acute hepatitis B virus-related hepatitis. <i>Histopathology</i> , 2012, 61, 881-888.	1.6	2
378	1354 HEPATITIS C VIRUS REINFECTION FOLLOWING SUSTAINED VIROLOGICAL RESPONSE IN INTRAVENOUS DRUG USERS. <i>Journal of Hepatology</i> , 2012, 56, S532.	1.8	2

#	ARTICLE	IF	CITATIONS
379	Letter: renal tubular dysfunction during nucleotide analogue therapy in chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 36, 992-993.	1.9	2
380	Validation of the Baveno VI elastography criteria for the definition of compensated advanced chronic liver disease: an individual patient meta-analysis. <i>Journal of Hepatology</i> , 2017, 66, S69.	1.8	2
381	Clinical and epidemiological characteristics of hepatitis C virusinfected people who inject drugs: a Greek descriptive analysis. <i>Annals of Gastroenterology</i> , 2018, 31, 598-603.	0.4	2
382	Metastatic Signet-Ring Cell Carcinoma of the Skin. <i>American Journal of Gastroenterology</i> , 2018, 113, 1427.	0.2	2
383	Comparison of the Uptake of Screening Colonoscopy between Physicians and the General Population in Greece. <i>Digestive Diseases</i> , 2020, 38, 23-30.	0.8	2
384	Final analysis of the international observational S-Collate study of peginterferon alfa-2a in patients with chronic hepatitis B. <i>PLoS ONE</i> , 2020, 15, e0230893.	1.1	2
385	Platelet activation and hypercoagulability in patients with early primary biliary cholangitis compared with healthy controls. <i>Annals of Gastroenterology</i> , 2021, 34, 229-234.	0.4	2
386	The role of hepatitis E virus (HEV) infection in acute non-A, non-B hepatitis in Greece. <i>Hepatology</i> , 1994, 19, 1116.	3.6	2
387	Significance of HBV viremia levels estimated by a quantitative PCR assay in the evaluation of HBeAg negative chronic HBV infection. <i>Journal of Hepatology</i> , 2001, 34, 115.	1.8	2
388	Boceprevir for chronic HCV genotype 1 infection in treatment-experienced patients with severe fibrosis or cirrhosis: The Greek real-life experience. <i>Annals of Gastroenterology</i> , 2015, 28, 481-6.	0.4	2
389	Editorial: similar risk of hepatocellular carcinoma in chronic hepatitis B patients treated with tenofovir or entecavir—new clues from Europe. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 657-658.	1.9	2
390	Precore mutant chronic hepatitis B - approach to management. <i>MedGenMed: Medscape General Medicine</i> , 2003, 5, 1.	0.2	2
391	CO2 portography-investigation of choice in portal vein assessment?. <i>Journal of Hepatology</i> , 1998, 28, 148.	1.8	1
392	Hepatocellular carcinoma (HCC) and extrahepatic malignancies in primary biliary cirrhosis (PBC). <i>Journal of Hepatology</i> , 2001, 34, 184.	1.8	1
393	Gastro-esophageal reflux disease (GERD) in the Greek general population. <i>Gastroenterology</i> , 2003, 124, A541-A542.	0.6	1
394	14 Donor age does not influence progression of HCV recurrence after liver transplantation. <i>Journal of Hepatology</i> , 2004, 40, 6-7.	1.8	1
395	Hepatocellular carcinoma presenting with pleuritic pain. <i>European Journal of Internal Medicine</i> , 2006, 17, 222.	1.0	1
396	Reply to Dr. Krag et al.. <i>Endoscopy</i> , 2007, 39, 374-374.	1.0	1

#	ARTICLE	IF	CITATIONS
397	[749] SERUM APOPTOTIC CASPASE ACTIVITY AS MARKER OF DISEASE SEVERITY IN CHRONIC HEPATITIS C (CH-C) OR NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD). <i>Journal of Hepatology</i> , 2007, 46, S282.	1.8	1
398	P.1.48: EFFECTIVENESS AND SAFETY OF TENOFOVIR DISOPROXIL FUMARATE IN FIELD PRACTICE: A MULTICENTER EUROPEAN COHORT STUDY OF 737 PATIENTS WITH CHRONIC HEPATITIS B. <i>Digestive and Liver Disease</i> , 2011, 43, S164.	0.4	1
399	The safety of anti-TNF therapy in patients with hepatitis B and C virus infection. <i>International Journal of Clinical Rheumatology</i> , 2012, 7, 191-196.	0.3	1
400	P1251 : Hepatitis B and C: Knowledge, attitudes and preventive practices of the Greek general adult population. Preliminary results of the Greek national health examination survey <i>Journal of Hepatology</i> , 2015, 62, S826-S827.	1.8	1
401	503 High SVR Rates in Patients with Genotype 4 Chronic Hepatitis C Infection and Compensated Cirrhosis With Ombitasvir/Paritaprevir/Ritonavir Co-Administered With Ribavirin (AGATE-I). <i>Gastroenterology</i> , 2016, 150, S1037.	0.6	1
402	A Genotype-Specific Baseline Score to Predict Post-Treatment Response to Peginterferon Alfa-2a in HBeAg-Positive Patients with Hepatitis B Virus Genotype B or C Infection. <i>Journal of Hepatology</i> , 2016, 64, S589-S590.	1.8	1
403	Effectiveness of Peginterferon Alfa-2a Therapy in HBeAg-Positive and HBeAg-Negative Patients with Chronic Hepatitis B: Final Results 3 Years Post-Treatment of the Prospective, Global, Observational S-Collate Study. <i>Journal of Hepatology</i> , 2016, 64, S598-S599.	1.8	1
404	The Impact of Age on Fibrosis Progression in Chronic Hepatitis C Patients. <i>Journal of Hepatology</i> , 2016, 64, S459-S460.	1.8	1
405	HBsAg Loss with Tenofovir Disoproxil Fumarate Plus Peginterferon Alfa-2A in Chronic Hepatitis B: Long-Term Results of a Global Randomized Controlled Trial. <i>Journal of Hepatology</i> , 2016, 64, S524-S525.	1.8	1
406	Predictors of Sustained Virological Response (SVR) in Patients with Advanced Chronic Hepatitis C (CHC) Treated with Current Direct Acting Antiviral(s) (DAA). <i>Heraclis: Hellenic Multicenter Real-Life Cohort Study. Gastroenterology</i> , 2017, 152, S1093.	0.6	1
407	FRI-175-Frequency, severity and impact of Peg-IFNa-associated flares in HDV infection: Results from the HIDIT-II study. <i>Journal of Hepatology</i> , 2019, 70, e466.	1.8	1
408	THU-427-A community-based fast-track seek-test-treat program to enhance diagnosis and linkage to care for hepatitis C infection among people who inject drugs in Athens, Greece (ARISTOTLE HCV-HIV) <i>Tj ETQq0 0 0 rgBT1/0verlock110 Tf 50 2</i>		
409	SAT-037-Appling the new nutritional screening and assessment algorithm to estimate malnutrition prevalence in Greek cirrhotic patients as suggested by the 2018 EASL nutritional guidelines for chronic liver disease. <i>Journal of Hepatology</i> , 2019, 70, e642-e643.	1.8	1
410	The clinical and patient reported outcomes (PROs) profile of patients with non-alcoholic fatty liver disease (NAFLD) from real-world practices varies across the world. <i>Journal of Hepatology</i> , 2020, 73, S111.	1.8	1
411	Real-world experience from tenofovir alafenamide use in chronic hepatitis B: an Hellenic multicenter real-life clinical study (HERACLIS-TAF). <i>Journal of Hepatology</i> , 2020, 73, S865-S866.	1.8	1
412	Reply to: <i>Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B</i> . <i>Journal of Hepatology</i> , 2021, 74, 246-247.	1.8	1
413	New prognostic score based on galectin-3 has similar performance to model for end-stage liver disease and sodium score in patients with stable decompensated cirrhosis. <i>Annals of Gastroenterology</i> , 2021, 34, 728-735.	0.4	1
414	Chronic Hepatitis B Virus Infection: Interferon Therapy and Long-Term Outcomes. , 2021, , 267-285.		1

#	ARTICLE	IF	CITATIONS
415	The Significance of Circulating Cell-Free DNA Markers in Chronic Hepatitis B Patients with Hepatocellular Carcinoma. <i>Pathogens</i> , 2021, 10, 1524.	1.2	1
416	Amineptine induced liver injury. Report of two cases and brief review of the literature. <i>Hepato-Gastroenterology</i> , 1996, 43, 1015-9.	0.5	1
417	Pericarditis and possible antiphospholipid syndrome on primary biliary cirrhosis. <i>Annals of Hepatology</i> , 2004, 3, 167-8.	0.6	1
418	Drug evaluation: LB-80380—a novel phosphonate nucleoside for the potential treatment of HBV infection. <i>Current Opinion in Molecular Therapeutics</i> , 2006, 8, 352-7.	2.8	1
419	Correlation between the BCL-2, P53 and MDM2 protein expression in colorectal adenocarcinomas. <i>Gastroenterology</i> , 1998, 114, A694.	0.6	0
420	Immunohistochemical staining for BCL-2 and P53 in gastric adenocarcinomas. <i>Gastroenterology</i> , 1998, 114, A692.	0.6	0
421	Apoptosis through different stages of colorectal tumorigenesis. <i>Gastroenterology</i> , 2000, 118, A1415.	0.6	0
422	Efficacy of long term lamivudine therapy in HBeAg negative chronic hepatitis B. <i>Gastroenterology</i> , 2000, 118, A1004.	0.6	0
423	Interferon therapy for prevention of hepatocellular cancer in patients with HCV related cirrhosis: A meta-analysis. <i>Gastroenterology</i> , 2000, 118, A1478.	0.6	0
424	Course of virologic breakthroughs (VBTs) under lamivudine (LAM) therapy in patients (PTS) with precore mutant HBV related chronic liver disease (CLD). <i>Journal of Hepatology</i> , 2001, 34, 143.	1.8	0
425	Mesenteric venous thrombosis after transcatheter arterial chemoembolization for hepatocellular carcinoma. <i>American Journal of Gastroenterology</i> , 2002, 97, 2685-2686.	0.2	0
426	HCV recurrence after OLT: no influence of donor age or sex mismatch on fibrosis—a prospectively biopsied cohort. <i>Journal of Hepatology</i> , 2002, 36, 32.	1.8	0
427	Is there any effect of propranolol therapy on the development of spontaneous bacterial peritonitis (SBP) in cirrhotic patients with ascites?. <i>Journal of Hepatology</i> , 2002, 36, 59-60.	1.8	0
428	Characteristics and outcome of biochemical breakthroughs (BBTs) in patients with HBeAg-negative HBV related chronic liver disease [HBeAg(-)CLD] under long-term lamivudine monotherapy (LAM). <i>Journal of Hepatology</i> , 2002, 36, 122.	1.8	0
429	Thrombotic risk factors and extent of liver fibrosis in patients with chronic viral hepatitis (CH). <i>Journal of Hepatology</i> , 2002, 36, 175.	1.8	0
430	Mycophenolate mofetil (MMF) monotherapy improves renal dysfunction in orthotopic liver transplant (OLT) recipients without increased risk of rejection. <i>Journal of Hepatology</i> , 2002, 36, 193.	1.8	0
431	Long-term lamivudine monotherapy (LAM) in patients with HBeAg-negative HBV related chronic liver disease [HBeAg(-)CLD]: predictors of virological (VBTs) and biochemical (BBTs) breakthroughs. <i>Journal of Hepatology</i> , 2002, 36, 242-243.	1.8	0
432	Diabetes mellitus (DM) and staging of chronic viral hepatitis (CH). <i>Journal of Hepatology</i> , 2002, 36, 272.	1.8	0

#	ARTICLE	IF	CITATIONS
433	Treatment of HBEAG-negative chronic hepatitis B (CHBE-) with sequential lamivudine (LAM) and Interferon-ALFA (IFN) courses of 12-month duration and a 6-month overlap. Journal of Hepatology, 2003, 38, 152-153.	1.8	0
434	409 dating the HCV3a epidemic in greece using molecular clock approaches. Journal of Hepatology, 2006, 44, S154.	1.8	0
435	594 Natural course of treated and untreated chronic HCV infection: Results of the nationwide HEPNET. Greece cohort study. Journal of Hepatology, 2006, 44, S220-S221.	1.8	0
436	633 HLA disparity is associated with ulcerative colitis course after transplantation for PSC. Journal of Hepatology, 2006, 44, S235.	1.8	0
437	PGI17 DEPICTION OF GASTROESOPHAGEAL REFLUX DISEASE (GERD) PREVALENCE IN PRIMARY CARE IN GREECE. Value in Health, 2006, 9, A246.	0.1	0
438	[480] LONGITUDINAL CHANGES IN SERUM HBV-DNA LEVELS DURING THE NATURAL COURSE OF HBeAg-NEGATIVE CHRONIC HEPATITIS B VIRUS (HBV) INFECTION. Journal of Hepatology, 2007, 46, S182.	1.8	0
439	PGI29 UPPER GI SYMPTOMS IN GREEK PATIENTS RECEIVING ASPIRIN/NSAIDS. Value in Health, 2007, 10, A360.	0.1	0
440	PG132 CORRELATION BETWEEN THE SEVERITY OF UPPER GASTROINTESTINAL (GI) SYMPTOMS AND ENDOSCOPIC FINDINGS IN THE GREEK PRIMARY CARE SETTING. Value in Health, 2008, 11, A528.	0.1	0
441	Changes of liver and muscle enzymes activity in patients with rigor. European Journal of Internal Medicine, 2008, 19, 109-114.	1.0	0
442	570 CLINICAL EVALUATION OF THE ARMS RT-PCR FOR THE QUANTITATIVE DETECTION OF M204V VARIANTS IN CHRONIC HBV PATIENTS. Journal of Hepatology, 2008, 48, S214.	1.8	0
443	453 PATIENTS WITH RECURRENT HCV INFECTION AND UNDER ANGIOTENSIN RECEPTOR BLOCKERS AFTER LIVER TRANSPLANTATION HAVE SLOWER HISTOLOGICAL PROGRESSION. Journal of Hepatology, 2009, 50, S171.	1.8	0
444	731 CHANGES OF SERUM APOPTOTIC CASPASE ACTIVITY IN HBEAG-NEGATIVE CHRONIC HEPATITIS B (CHB) PATIENTS UNDER ORAL ANTIVIRAL THERAPY. Journal of Hepatology, 2010, 52, S284-S285.	1.8	0
445	Similar Efficacy of Antiviral Therapy in Chronic Hepatitis C (CHC) Patients With Genotype 1 (G1) or Genotype 4 (G4). Results of a Large Nationwide Cohort Study. Gastroenterology, 2011, 140, S-949.	0.6	0
446	1117 DETECTION OF MINORITY HBV RESISTANT STRAINS IN HBV TREATMENT NAIVE PATIENTS USING A HIGHLY SENSITIVE ASSAY BASED ON ARMS RT-PCR WITH MOLECULAR BEACON. Journal of Hepatology, 2011, 54, S442.	1.8	0
447	F-36 Effectiveness and safety of tenofovir disoproxil fumarate in field practice: A multicenter European cohort study of 737 patients with chronic hepatitis B. Digestive and Liver Disease, 2011, 43, S103-S104.	0.4	0
448	142 LEFT VENTRICLE ENLARGEMENT AND HIGHER SYSTOLIC VELOCITY IN MITRAL VALVE ARE INDIRECT MARKERS OF HEPATOPULMONARY SYNDROME. Journal of Hepatology, 2011, 54, S62.	1.8	0
449	385 SIGNIFICANCE OF TRANSIENT ELASTOGRAPHY (TE) IN HBEAG-NEGATIVE CHRONIC HBV CARRIERS. Journal of Hepatology, 2011, 54, S154-S155.	1.8	0
450	459 FREQUENCY AND PREDICTORS OF NO TREATMENT IN ANTI-HCV POSITIVE PATIENTS AT TERTIARY LIVER CENTERS. Journal of Hepatology, 2011, 54, S187.	1.8	0

#	ARTICLE	IF	CITATIONS
451	470 DOES HEPATIC STEATOSIS OR OBESITY INFLUENCE THE EFFICACY OF PEGYLATED INTERFERONS DIFFERENTLY?. Journal of Hepatology, 2011, 54, S192.	1.8	0
452	Entecavir treatment in HBV-related decompensated cirrhosis. Future Virology, 2011, 6, 1275-1281.	0.9	0
453	Effect of antiviral therapy on the immunohistochemical expression of bcl-2 and bax protein in patients with HBeAg-negative chronic hepatitis B. Journal of Medical Virology, 2011, 83, 1165-1171.	2.5	0
454	481 THE USEFULNESS OF TRANSIENT ELASTOGRAPHY (TE) IN THE ACCURATE ASSESSMENT OF PATIENTS WITH HBEAG-NEGATIVE CHRONIC HBV INFECTION (CHBVE-). Journal of Hepatology, 2012, 56, S189-S190.	1.8	0
455	511 HBSAG LEVELS DECLINE DURING PEGINTERFERON ALFA-2A [40KD] (PEGASYS) TREATMENT IN PATIENTS WITH HBEAG-NEGATIVE CHRONIC HEPATITIS B FAVORS 6 MONTHS POST-TREATMENT RESPONSE: PERSEAS COHORT INTERIM ANALYSIS. Journal of Hepatology, 2012, 56, S201-S202.	1.8	0
456	1305 ASSOCIATION BETWEEN ADHERENCE TO THE MEDITERRANEAN DIET (MD) AND CLINICAL CHARACTERISTICS OF PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD). Journal of Hepatology, 2012, 56, S514-S515.	1.8	0
457	435 ANTI-HDV-IgM AS A MARKER OF DISEASE ACTIVITY IN HEPATITIS DELTA. Journal of Hepatology, 2013, 58, S178.	1.8	0
458	P0716 : The significance of platelet microparticles in patients with chronic hepatitis C and their association with antiviral treatment and smoking. Journal of Hepatology, 2015, 62, S592.	1.8	0
459	P0793 : Estimating the number of chronic hepatitis C patients in need of treatment and projecting the disease burden during 2015-2030 under the interferon-free treatment regimens in Greece. Journal of Hepatology, 2015, 62, S630.	1.8	0
460	Controversial Issues in Current Treatment of Chronic HBV Infection. Current Hepatology Reports, 2015, 14, 164-170.	0.4	0
461	Advanced glycation end products and the pathogenesis of nonalcoholic fatty liver disease in non-diabetic adults. Proceedings of the Nutrition Society, 2016, 75, .	0.4	0
462	Genetic Variation in FCER1A Gene Predicts Sustained HBsAg Clearance in East-Asian Patients Treated with Pegylated Interferon Alfa-2a (40kd): The "Peg-Be-Yond" Study. Journal of Hepatology, 2016, 64, S603.	1.8	0
463	Case 21-2016: A Man in an Unresponsive State. New England Journal of Medicine, 2016, 375, 1697-1697.	13.9	0
464	Normal Values of Liver Stiffness as Measured by Transient Elastography: Pooled Individual Participant Data Meta-Analysis from 26 Studies and 14,883 Participants. Gastroenterology, 2017, 152, S1106.	0.6	0
465	Association Between Scleroderma Esophagus and Systemic Sclerosis Manifestations. Gastroenterology, 2017, 152, S699.	0.6	0
466	HBsAg Loss With TDF Plus PegIFN in Chronic Hepatitis B (CHB): Long-term Results of a Global Randomized Controlled Trial. Clinical Gastroenterology and Hepatology, 2017, 15, e45.	2.4	0
467	Platelets represent an independent predictor of sustained virological response (SVR) in patients with advanced chronic hepatitis C (CHC) treated with current direct acting antiviral(s) (DAA). HERACLIS: Hellenic multicenter real-life cohort study. Journal of Hepatology, 2017, 66, S502.	1.8	0
468	Impact of elbasvir/grazoprevir (EBR/GZR) on health-related quality of life (HRQOL) and fatigue in patients with chronic hepatitis C virus (HCV) infection and inherited blood disorders (IBLD): data from the C-EDGE IBLD study. Journal of Hepatology, 2017, 66, S521-S522.	1.8	0

#	ARTICLE	IF	CITATIONS
469	Normal values of liver stiffness as measured by transient elastography: pooled individual participant data meta-analysis from 26 studies and 14,883 participants. <i>Journal of Hepatology</i> , 2017, 66, S238.	1.8	0
470	Comorbidities in chronic hepatitis B patients currently treated with nucleos(t)ide analogues. <i>Journal of Hepatology</i> , 2018, 68, S492.	1.8	0
471	Scale up of hepatitis C virus treatment in the era of all-oral direct-acting antivirals: a 9-year Greek cohort study. <i>Journal of Hepatology</i> , 2018, 68, S163-S164.	1.8	0
472	FRI-197-Prediction of elastographic reversion of cirrhosis after 5 years of entecavir or tenofovir disoproxil fumarate therapy in caucasian chronic hepatitis B patients. <i>Journal of Hepatology</i> , 2019, 70, e477-e478.	1.8	0
473	Factors associated with failure to link people who inject drugs to HCV care and treatment: results from a community-based seek-test-treat program in Athens, Greece (ARISTOTLE HCV-HIV). <i>Journal of Hepatology</i> , 2020, 73, S830.	1.8	0
474	Reply to: "Clinical relevance of dynamic risk assessment for developing hepatocellular carcinoma during prolonged antiviral therapy". <i>Journal of Hepatology</i> , 2020, 73, 223-224.	1.8	0
475	Microalbuminuria in NAFLD patients: The impact of cardiovascular system. <i>Liver International</i> , 2021, 41, 1164-1165.	1.9	0
476	Management of Patients with Renal Impairment: Direct-Acting Antivirals and Renal Function. , 2021, , 175-190.		0
477	Course of virologic breakthroughs under lamivudine therapy in patients with precore mutant HBV related liver disease. <i>Gastroenterology</i> , 2001, 120, A385-A385.	0.6	0
478	Histological features of acute non-A, non-B hepatitis: Hepatitis C versus non-A, non-B, non-C hepatitis. <i>Hepatology</i> , 1993, 18, A146.	3.6	0
479	Significance of anti-HBc IgM by a microparticle enzyme immunoassay in the differential diagnosis of acute HBsAg-positive hepatitis. <i>Hepatology</i> , 1993, 18, A258.	3.6	0
480	The natural history of community-acquired non-A, non-B, non-C, non-E hepatitis. <i>Hepatology</i> , 1994, 19, I131.	3.6	0
481	Long-term remission of chronic HBeAg positive hepatitis B after alfa-interferon treatment. <i>Hepatology</i> , 1994, 19, I132.	3.6	0
482	Hepatitis C virus infection in parenteral drug abusers. <i>Hepatology</i> , 1994, 19, I114.	3.6	0
483	Greek results of the "ENERGIB" European study on non-variceal upper gastrointestinal bleeding. <i>Annals of Gastroenterology</i> , 2012, 25, 327-332.	0.4	0
484	Long-term outcome of chronic hepatitis C treated with interferon. <i>Italian Journal of Gastroenterology and Hepatology</i> , 1999, 31, 459-61.	0.5	0
485	Hippocratic views in the treatment of rectal prolapse. <i>Acta Gastro-Enterologica Belgica</i> , 2017, 80, 411-415.	0.4	0